Trial Profile
Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Olvimulogene nanivacirepvec (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genelux Corporation
- 30 May 2012 Results are to be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012), according to a Genelux media release.
- 20 Apr 2012 Additional lead trial investigator (Hardev Pandha) identified as reported by ClinicalTrials.gov.
- 12 Sep 2011 Actual end date September 2011 added as reported by ClinicalTrials.gov.